Inspire Investing LLC Buys 303 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Inspire Investing LLC grew its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 13.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,601 shares of the medical instruments supplier’s stock after buying an additional 303 shares during the period. Inspire Investing LLC’s holdings in ICU Medical were worth $404,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. Barclays PLC lifted its holdings in ICU Medical by 15.6% during the third quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier’s stock worth $10,790,000 after acquiring an additional 8,010 shares in the last quarter. LMR Partners LLP bought a new position in shares of ICU Medical during the 3rd quarter valued at about $3,884,000. Principal Financial Group Inc. grew its position in shares of ICU Medical by 24.6% in the 3rd quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier’s stock valued at $23,130,000 after purchasing an additional 25,031 shares during the period. MetLife Investment Management LLC increased its stake in ICU Medical by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 12,389 shares of the medical instruments supplier’s stock worth $2,258,000 after purchasing an additional 6,981 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in ICU Medical by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock worth $99,687,000 after buying an additional 48,106 shares during the period. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Price Performance

NASDAQ:ICUI opened at $172.30 on Friday. ICU Medical, Inc. has a 52-week low of $86.80 and a 52-week high of $196.26. The company has a market cap of $4.22 billion, a P/E ratio of -37.70 and a beta of 0.63. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The stock’s 50-day simple moving average is $161.06 and its 200 day simple moving average is $160.84.

Analyst Ratings Changes

ICUI has been the topic of a number of research analyst reports. KeyCorp raised their price objective on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Jefferies Financial Group raised ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price on the stock in a research report on Wednesday, December 11th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, ICU Medical currently has an average rating of “Moderate Buy” and an average price target of $199.67.

Insider Activity

In other ICU Medical news, Director David C. Greenberg sold 972 shares of the company’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $158.11, for a total value of $153,682.92. Following the transaction, the director now directly owns 5,037 shares in the company, valued at $796,400.07. The trade was a 16.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Vivek Jain sold 12,000 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at $17,973,261.12. The trade was a 10.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,737 shares of company stock valued at $4,941,832. 6.70% of the stock is owned by company insiders.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.